ELGAN Pharma

About

Funding history · 3 rounds · $7.5M total

Headcount over time

Q&A

What is ELGAN Pharma's primary focus?

ELGAN Pharma is a late-stage clinical biopharmaceutical company that develops therapies for preterm infants, addressing medical problems and developmental difficulties common in babies born very early.

What are ELGAN Pharma's two leading clinical programs?

ELGAN Pharma's two leading clinical programs are ELGN-GI, which promotes faster maturation of an infant's intestines, and ELGN-EYE, aimed at preventing vision impairment due to retinopathy of prematurity (ROP).

What was the most recent funding event for ELGAN Pharma?

In July 2023, ELGAN Pharma received a Grant of $2,590,000, with the.

What was the outcome of the Phase III study for ELGN-GI?

In March 2022, ELGAN Pharma announced positive results from its Phase III study of ELGN-GI in preterm infants for the treatment of intestinal malabsorption.

When did ELGAN Pharma begin dosing infants in the Phase 3 study of ELGN-2112?

In June 2025, ELGAN Pharma and Chiesi Group announced the dosing of the first participating infants in the FIT-PIV Phase 3 clinical study for ELGN-2112, which treats intestinal malabsorption in preterm infants.

How many employees does ELGAN Pharma currently have?

ELGAN Pharma has 20 employees, falling within the 11-50 employee bucket.

Who are the co-founders of ELGAN Pharma?

The co-founders of ELGAN Pharma are Miki Olshansky, who serves as CEO, and Stav Zeldis, who is the VP Regulatory Affairs.

What is the total amount of funding ELGAN Pharma has raised to date?

ELGAN Pharma has raised a total of $10,047,720 USD.

Team · 2

Miki Olshansky

Founder · Co-founder & CEO

Stav Zeldis

Founder · Co-founder & VP Regulatory Affairs

Sectors & technology

Highlights

Tags